INDIA MUCORMYCOSIS TREATMENT (BLACK FUNGUS DRUGS) MARKET ANALYSIS

Market Challenges And Opportunities

India Mucormycosis Treatment (Black Fungus Drugs) Market – Restraints

High cost of the medicines for the treatment of mucormycosis is expected to restrain growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period. For instance, the only antifungal drug, Amphotericin B is expensive and it will be difficult for the people to bear the cost. Currently the single vial of the drug is available in the market at a price of US$ 68.6 to US$ 109.9 (5,000 to 8,000 Indian rupees). Moreover the medicines have to be taken for 4 to 12 weeks, thus, many patients fail to take the treatment due to high cost. Government intervention may help in curbing the cost of the medicines.

Furthermore, drug shortages is another factor, which may hamper growth of the market. For instance, Kerala, a state in South India, declared Amphotericin B shortage in the market. Moreover, on an average a mucormycosis patient requires 100 vials of Amphotericin B for their treatment. Thus, India will require 9 to 10 lakhs injections of Amphotericin B for 9,000 mucormycosis patients. Thus, the above factors are expected to restrain the growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecast period.

Figure 2: India Mucormycosis Treatment (Black Fungus Drugs) Market Value (US$ Mn) & Y-o-Y Growth (%), 2020 - 2028